Erlotinib Recruiting Phase 2 Trials for NSCLC Stage II / Non-small Cell Lung Cancer Stage IIIA / NSCLC, Stage IIIA / Epithelial Growth Factor Receptor Positive Non-small Cell Lung Cancer / Lung Cancer Non-Small Cell Stage II Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01470716Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
NCT01410214Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations